CTLA-4在肺癌中的研究进展  

Research progress of CTLA-4 in lung cancer

作　　者：李丽 陈公琰[1] LI Li;CHEN Gongyan(Harbin Medical University Cancer Hospital,Heilongjiang Harbin 150000,China)

机构地区：[1]哈尔滨医科大学附属肿瘤医院,黑龙江哈尔滨150000

出　　处：《现代肿瘤医学》2021年第2期348-352,共5页Journal of Modern Oncology

摘　　要：细胞毒性T淋巴细胞相关抗原-4(cytotoxic T lymphocyte-associated antigen-4,CTLA-4)是一种白细胞分化抗原,也是T细胞上的一种跨膜受体,目前针对CTLA-4在抑制T细胞免疫应答中所起作用的研究取得了一定的突破和成绩,与程序性死亡受体1(programmed death receptor-1,PD-1)共同打开了肿瘤治疗的新局面。通过对上述两个靶点的抑制,可以激活免疫系统,增强T细胞介导的免疫反应,从而增强患者的抗肿瘤能力,并且相应的免疫检查点抑制剂(例如抗CTLA-4单克隆抗体Ipilimumab)已用于黑色素瘤、肺癌等癌种的临床治疗。现就CTLA-4、抗CTLA-4单克隆抗体在肺癌中的作用机制及研究进展作一综述。Cytotoxic T lymphocyte-associated antigen-4(CTLA-4)is a leukocyte differentiation antigen and a transmembrane receptor on T cells.It is currently inhibiting T cells against CTLA-4.The research on the role of immune response has made some breakthroughs and achievements,and together with programmed death receptor-1(PD-1)opened a new situation in cancer therapy.By inhibiting these two targets,the immune system can be activated to enhance T cell-mediated immunity,thereby enhancing the patient's anti-tumor ability,and the corresponding immune checkpoint inhibitor(such as anti-CTLA-4 monoclonal antibody Ipilimumab)has been used in clinical treatment of cancers such as melanoma and lung cancer.The mechanism and research progress of CTLA-4 and anti-CTLA-4 monoclonal antibodies in lung cancer are reviewed.

关 键 词：CTLA-4 肺癌 抗CTLA-4单克隆抗体 肺癌免疫治疗 

分 类 号：R734.2[医药卫生—肿瘤]